Potential for use sunitinib in pancreatic neuroendocrine tumors

Abstract

The treatment efficacy and toxicity profile was evaluated in 33 patients with highly differentiated neuroendocrine tumors NEO (G1, G2), who received sunitinib therapy in various dose regimens. Stable disease was achieved in 24 patients (72.7%), partial effect in 1 patient (3%). The efficacy of treatment did not depend on the used dose regimen. The toxicity profile was consistent with international study data.

Keywords

• neuroendocrine tumors
• sunitinib
• safety profile